ArticleTurk psikiyatri dergisi = Turkish journal of psychiatry2026
The Diagnostic Role of FDG-PET in Dementias Presenting with Language and Behavioral Symptom.
Article in Turk psikiyatri dergisi = Turkish journal of psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to assess the diagnostic contribution of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in neurodegenerative dementias presenting with language-predominant symptoms, with or without accompanying behavioral changes, and to evaluate the correspondence between PET-derived metabolic patterns and cerebrospinal fluid (CSF) biomarkers.
methodsSixteen patients with language-predominant onset were categorized into two groups: Alzheimer’s disease (AD) spectrum (n=8) and the frontotemporal lobar degeneration (FTLD) spectrum (n=8). All participants underwent clinical evaluation, neuropsychological testing, and FDG-PET imaging. Cerebrospinal fluid biomarkers [Amyloid Beta (Aβ42), total tau, and phosphorylated tau] were analyzed in eligible individuals (n=6). The two groups were compared across demographic, clinical, and neuroimaging parameters.
resultsFDG-PET revealed pronounced posterior temporoparietal hypometabolism in AD-spectrum patients, whereas FTLD-spectrum patients demonstrated frontal, insular, and anterior temporal metabolic involvement. Cerebrospinal fluid biomarker profiles consistently supported Alzheimer-type pathology among AD-spectrum cases. In the FTLD group, one patient exhibited borderline-low Aβ42; however, the corresponding FDG-PET pattern was characteristic of FTLD.
conclusionFDG-PET demonstrates a supportive role in differentiating AD from FTLD among patients presenting with language-predominant neurodegenerative syndromes. In scenarios where CSF biomarkers are unavailable or yield borderline values, FDG-PET-based metabolic signatures may offer additional guidance and can contribute to strengthening multimodal diagnostic frameworks in geropsychiatry settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.